Cover Image

Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL

The efficacy of and disease control afforded by tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia in chronic phase (CML-CP) have led to increased longevity and thus the continued pursuit of alternative therapies that are efficacious and maximize tolerability. The 24- and 96-week analyses...

Full description

Saved in:
Bibliographic Details
Main Authors: Mauro, Michael J. (Author) , Minami, Yosuke (Author) , Hochhaus, Andreas (Author) , Lomaia, Elza (Author) , Voloshin, Sergey (Author) , Turkina, Anna (Author) , Kim, Dong-Wook (Author) , Apperley, Jane F. (Author) , Cortes, Jorge E. (Author) , Abdo, Andre (Author) , Fogliatto, Laura Maria (Author) , Kim, Dennis Dong Hwan (Author) , le Coutre, Philipp (Author) , Saußele, Susanne (Author) , Annunziata, Mario (Author) , Hughes, Timothy P. (Author) , Chaudhri, Naeem (Author) , Chee, Lynette (Author) , García-Gutiérrez, Valentin (Author) , Sasaki, Koji (Author) , Boquimpani, Carla (Author) , Kapoor, Shruti (Author) , Espurz, Noemi (Author) , Dhamal, Vishal (Author) , Rea, Delphine (Author)
Format: Article (Journal)
Language:English
Published: 26 AUGUST 2025
In: Blood advances
Year: 2025, Volume: 9, Issue: 16, Pages: 4248-4259
ISSN:2473-9537
DOI:10.1182/bloodadvances.2025016042
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/bloodadvances.2025016042
Get full text
Author Notes:Michael J. Mauro, Yosuke Minami, Andreas Hochhaus, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Jane F. Apperley, Jorge E. Cortes, Andre Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Lynette Chee, Valentin García-Gutiérrez, Koji Sasaki, Carla Boquimpani, Shruti Kapoor, Noemi Espurz, Vishal Dhamal, and Delphine Rea
Description
Summary:The efficacy of and disease control afforded by tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia in chronic phase (CML-CP) have led to increased longevity and thus the continued pursuit of alternative therapies that are efficacious and maximize tolerability. The 24- and 96-week analyses from ASCEMBL demonstrated superior efficacy, safety, and tolerability of asciminib when compared with bosutinib in later-line therapy, thereby meeting the primary and key secondary objectives. With nearly 4 years of follow-up, data from ASCEMBL continued to demonstrate the superior efficacy, safety, and tolerability of asciminib over bosutinib. At week 156, the major molecular response (MMR) rates remained higher with asciminib (33.8%) than with bosutinib (10.5%); the difference in MMR rates between arms, after adjusting for baseline major cytogenetic response, was 23.2% (95% confidence interval, 13.14-33.18; 2-sided P < .001). Asciminib continued to cause fewer grade ≥3 adverse events (AEs; 59.6% vs 68.4%) and fewer AEs that led to treatment discontinuation (8.3% vs 27.6%) than bosutinib. This updated analysis also includes patients who switched to asciminib because of a lack of efficacy with bosutinib. Two of the 25 patients who switched achieved MMR by the end of study, suggesting that earlier incorporation of asciminib, before other TKIs, may improve responses, albeit modestly. These long-term results further solidify asciminib as the therapy of choice for patients with CML-CP who were previously treated with ≥2 previous TKIs. This trial was registered at clinicaltrials.gov as #NCT03106779.
Item Description:Gesehen am 17.03.2026
Physical Description:Online Resource
ISSN:2473-9537
DOI:10.1182/bloodadvances.2025016042

Similar Items